KR20160018818A - Shaped-tablet slime remover - Google Patents

Abstract

Disclosure of the Invention A problem to be solved by the present invention is to provide a tablet for removing mucus that is used in intermittent or continuous running water and has high tablet strength and high initial dissolution concentration of sterilizing component and further, And to provide a tablet for removing or preventing slime.
The mucus removal tablet of the present invention is a mucus removal tablet used in intermittent or continuous water flow, and has the following form (A) and / or (B)
(A) a concave portion formed in the central portion of the upper surface of the tablet and /
(B) a through hole formed from the central portion of the upper surface of the tablet to the central portion of the tablet bottom surface
The elution concentration of the initial sterilizing component is high and the elution concentration of the long-term sterilizing component is a certain concentration or more.

Description

[0001] SHAPED-TABLET SLIME REMOVER [0002]

The present invention relates to purification of a mucus control agent which is installed at a point where mucus is generated by a metabolite such as a germ or mold such as a kitchen sink or a drain in a bathroom to remove mucus and prevent the occurrence of mucus.

Priority is claimed on Japanese Patent Application No. 2011-153775, filed on July 12, 2011, and Japanese Patent Application No. 2011-153819, the contents of which are incorporated herein by reference.

The mucus remover contains a medicament having a germicidal ingredient in the tablet, dissolving the medicament while dissolving the tablet, and sterilizing germs and the like which cause mucus by the germicidal ingredient to prevent mucus (Patent Document 1 Reference). The method of using the mucus remover is preferably such that when the mucus is removed, the concentration of the sterilizing component of the drug solution in which the drug is dissolved is high, and when the place where the mucus is removed is prevented from generating mucus for a long period of time, The concentration of the component is required to be longer than a certain level, and it is necessary to maintain it for a long time.

The mucus remover is used by being installed in a drainage part of a kitchen, a drainage part of a bathroom washroom, or the like, and is used under intermittent or continuous watery conditions depending on the usage form of the user. Therefore, unlike tablets (see Patent Document 2) used in an environment where a certain amount of water is always present, such as a bathing solvent in a bathtub of a bathroom, it is possible to appropriately dissolve the sterilizing component so as to adjust the concentration and duration of the sterilizing component There is a need.

However, conventional tablets are mainly in the form of tablets, and are excellent in the strength of tablets and ease of tableting, but the concentration of the sterilizing component is lowered with the use, and the concentration of effective sterilizing component is not reached. Even if the content of the sterilizing component is increased and the composition is improved, the tablet strength in the case of the composition having a high sterilizing component content is lowered and the dissolution rate is also lowered. Therefore, it is difficult to solve the problem only by changing the composition of the tablet. In addition, the method of changing the shape of the tablet into a plate to enlarge the surface area has not been able to withstand long-term use because the tablet is cracked immediately when it is used in water.

Other forms of tablets are known as follows. Patent Document 3 discloses a donut-shaped mucus-removing tablet, but it does not describe specifically what effect it has. Patent Document 4 describes an annular chemical agent tablet for swimming pools, and describes the effect of creating decomposition to obtain uniform dissolution. However, the side surface is wrapped with a plastic material, and the tablets It is not an invention. Patent Document 5 discloses a circular purification tank disinfection-disinfecting tablet for disinfection, and it has been described that the dissolution rate is 3 to 4 times that of a tablet having no perforation, but it is merely an invention to accelerate dissolution rate. Therefore, development of a mucus-preventing tablet having a high strength of tablets, a high initial sterilizing component concentration, and a long-term sterilizing component concentration of a certain concentration or more has been desired.

[Prior Art Literature]

[Patent Literature]

(Patent Document 1) Japanese Laid-Open Patent Publication No. 2000-327509

(Patent Document 2) JP-A-8-333236

(Patent Document 3) Japanese Laid-Open Patent Publication No. 2001-317101

(Patent Document 4) Japanese Published Patent Application No. 05-506607

(Patent Document 5) Japanese Patent Publication No. 63-15283

SUMMARY OF THE INVENTION The present invention has been made in view of the above-described circumstances of the prior art, and it is an object of the present invention to provide a mucilage-removing or mucus-preventing agent having a high tablet strength and capable of increasing an initial dissolution concentration of a sterilizing component, And to provide a tablet.

The tablet of the present invention is characterized in that it has a donut-shaped shape having a shape that forms a clinical area (concave portion) or a through hole.

In the conventional tablet-like tablet, the tablets are reduced with the dissolution of tablets, and the surface area is accordingly reduced. In addition, since it dissolves in a more streamlined shape, any part of the tablet maintains the same dissolution rate, and as a result, the elution of the sterilizing component decreases in proportion to the surface area of the tablet.

On the other hand, the concave portion and the through-hole of the present invention are not merely an effect of only increasing the surface area. Instead, the flow of water is made turbulent by the concave portion or the through hole under the water flow and the reflux of the concave portion or the through- The dissolution rate can be improved. As a result, the concave portion has a deeper concave portion because the dissolving speed is faster than other portions, and the penetrating hole has a faster dissolving speed than other portions, so that it becomes a wider through hole. As a result, the fast dissolution of the concave portion or the through-hole and the reduction of the surface area are suppressed, so that the sterilizing component can be eluted well in the whole tablet.

In addition, since the dissolution control can be performed only by the shape of the tablet, there is no case of lowering the tablet strength or lowering the initial dissolution concentration.

That is,

[1] A tablet for removing mucus used in intermittent or continuous running water,

(A) and / or (B).

(A) a concave portion formed in the central portion of the upper surface of the tablet and /

(B) a through hole formed from the central portion of the upper surface of the tablet to the central portion of the tablet bottom surface

[2] The mucilage purification tablet according to the above [1], wherein the mucilage purification tablet according to the above [1], which is stored in a mucus removal container having a structure in which water flows in,

[3] The mucilage purification tablet according to the above [2], wherein the time to be 50% or less of the total weight of the tablets in the continuous running water is 1 hour or more.

[4] The mucilage purification tablet according to any one of [1] to [3], wherein the depth of the concave portion is 3 to 20% of the diameter of the tablet or 5 to 30%

[5] The mucilaginous tablet according to any one of [1] to [3], wherein the diameter of the through-hole is 10 to 40% of the diameter of the tablet, and

[6] The mucilage purification tablet according to any one of [1] to [5], wherein the elution concentration of the initial sterilizing component is high and the elution concentration of the long-term sterilizing component is a certain concentration or more.

The tablet for removing mucus of the present invention is excellent in the following points in comparison with tablets of conventional shapes when used in intermittent or continuous running water.

1) It is possible to increase the amount of the drug eluted from the tablet without lowering the strength of the tablet.

2) When the elution concentration of the drug is lowered to such an extent that the use time is prolonged and sufficient effect can not be exhibited, it is possible to clearly indicate the time when the drug is broken into pieces and can not be used.

1 is a conceptual view from the upper surface of a cassette for removing mucus.
2 is a conceptual view of a cover for a kitchen drain.
3 is a view showing a shallow tablet with a concave portion.
Fig. 4 is a view showing a deep tablet with a concave portion. Fig.
5 is a view showing a tablet having a through-hole of 2.0 mmφ. In the figure, the R radius 12.55 indicates that the radius of the circle is 12.55 when the circular arc portion of the tablet is assumed to be a circle arc.
6 is a view showing tablets having different depths in the top and bottom of the concave portion.

The mucus removal tablet of the present invention is a mucus removal tablet used in intermittent or continuous water flow. The mucus removal tablet contains a concave portion at the central portion of the upper surface and / or a central portion of the bottom surface, The elution concentration of the initial sterilizing component is high and the elution concentration of the sterilizing component is a certain concentration or more over a long period of time.

(When the tablets have concave portions)

In one form of the tablet of the present invention, a concave portion is formed at the center of the upper surface of a general tablets and / or the center of the bottom surface. Typical refinements are tablets that show shapes such as fillet, columnar, rectangular, disk, stop log, square, elliptical, spherical, and the like. The concave refers to the depressed portion on the surface of the tablet, and the shape of the concave portion is not particularly limited as long as it can solve the problem of the present invention, but it is preferably inverted conical. The depth of the concave portion is not particularly limited as long as it is visually perforated, but is preferably 5 to 30% of the thickness of the tablets at the deepest portion, or 3 to 20% of the diameter of the tablets.

The upper surface of the tablet refers to the flat portion of the tablet and represents the upper portion when the tablet is placed with the surface having a larger area than the other flat portion of the tablet down. When the tablets are all curved surfaces, The upper part of the tablet when it can stand still. In the case where there are a plurality of the stationary methods capable of stably standing, it indicates the upper part of the tablet when it can be most stably positioned, and the most stable position when the center of the tablet is at the lowest position. Further, in the case where it can not be stably stood, the face having the largest projected area is the top face. The center of the top surface or the bottom surface of the tablets indicates that the center is substantially the center, that is, the portion excluding the edge portion, and does not show the center exactly. The edges of the tablets may be chamfered. The concave portion of the tablet may be at least one point in the center of the upper surface and / or the center of the bottom surface, and may have a concave portion on the side surface.

(When the tablets have through-holes)

In another form of the tablet of the present invention, a through hole is formed in the central portion of the bottom surface from the central portion of the upper surface of the general tablets. The through hole refers to a cavity toward the bottom surface from the surface of the tablet. The shape of the through hole is not particularly limited as long as it can solve the problem of the present invention, but it is preferable that the through hole is a straight through hole. The diameter of the through hole is not particularly limited, but is preferably 10 to 40% of the diameter of the tablet.

The through hole of the tablet may have at least one point connecting the center of the bottom surface to the center of the top surface, and may have a through hole at the side surface.

(When tablets have concave portions and through holes together)

The tablet of the present invention includes the case where the concave portion and the through hole are simultaneously satisfied. Specifically, there is a through hole in addition to the concave portion, a case where the through hole penetrates to the opposite side, or a case where the through hole penetrates a surface and a surface different from the surface having the concave portion. In this case, the water flow becomes more complex turbulence.

(Size of tablets)

The size of the tablets is not more than 60 mm, preferably not more than 30 mm, particularly preferably not more than 15 mm in the longest portion so as to be installed in a narrow container such as various drain pipes and kitchen waste containers.

(How to Use Tablets)

The method of using the tablet of the present invention is not particularly limited as long as it can solve the problems of the present invention, but it is used in a state where water is flowing (in running water). The effluent may be continuous or intermittent. Any method may be used to fix the tablet in the running water and any mechanism may be used, but it is preferable that the tablet is stored in a dedicated mucilage remover. It is preferable that the interior of the slime eliminator has a structure in which water flows in a predetermined direction.

Flowing in a constant direction does not always indicate that it is flowing in a constant direction, for example, when water is used in the kitchen to flow water into the container, and when water is drained from the container, Direction flow.

In general, it is known that the dissolution rate increases when the surface of the tablet, for example, has a concave portion or a through hole. However, since the mucus removal requires an effect of preventing mucus over a long period of time, it is not preferable to dissolve quickly. It is preferable to set the time to be 50% or less of the total weight of the tablets to 1 hour or more, preferably 1 day or more, and more preferably 10 days or more, by optimizing the composition of the tablets or the like.

Since the mucoadhesive agent of the present invention is generally small, it can be used in the form of being stored in a water-permeable container in order to prevent leakage of the mucoadhesive agent when it is further reduced in size by dissolution. The water-permeable container can be used as a container formed of various known permeable materials or a container formed of a non-water-permeable material and provided with openings capable of preventing leakage of miniaturized tablets and having adequate water permeability . As a material of the opening portion capable of preventing the outflow of the miniaturized tablets and having proper water permeability, a nonwoven fabric or a resin film having pores is preferably used.

The water-permeable container is preferably a variety of well-known stoppers such as a thread, a cord, a metal wire, a resin fixture, and an adhesive material for installing a container at a point intended for mucus control in a drain pipe or a kitchen waste container It is preferable to provide a hook such as an adhesive tape portion. It is also possible to use a water-permeable container in which a tablet portion is not provided between the two tablets, and this placement portion is placed on the upper edge of the periphery of the waste container (generally triangular corner) To form a form capable of controlling mucus.

(Drug used to remove mucus)

The medicament to be used in the mucus removal of the present invention is not particularly limited, but the medicament for dissolving the mucus, eliminating the mucus producing bacteria such as mucus, sterilizing the mucus producing bacteria, It is preferable to contain a component having an effect such as antimicrobial activity against bacteria. The medicines having the above effect may be exemplified by a chlorine-based disinfectant, a non-bleaching antimicrobial agent, an antimicrobial inorganic metal or a compound thereof, an antibiotic substance, a bacterium capable of removing mucus, and the like.

(Chlorine-based disinfectant)

Examples of the chlorine-based fungicide usable in the present invention include sodium chlorite, bleaching powder, highly bleached white powder, sodium hypochlorite, hypochlorous acid water and the like.

(Non-bleaching antibiotic)

Any non-bleaching antimicrobial agent that can be used in the present invention can be used as long as it does not generate chlorine gas by reacting with an acidic substance or the like during its use. For example, a compound known as a general antifungal agent or antimicrobial agent And natural oily liquids known to have an antibacterial action.

Examples of the antifungal agent or antibacterial agent that can be used in the present invention include 5-chloro-2-methyl-4-isothiazolin-3-one, 4,5-dichloro-3-n-octyl-isothiazolin-3-one, 1,2-benzisothiazolin-3-one, 2-methoxycarbonylbenzimidazole, -Tetrahydro-4-methanesulfonylpyridine, 2-thiocyanomethylthiobenzothiazole, 2,2-dithio-bis- (pyridine-1-oxide), 3,3,4,4-tetrahydrothiophene Dichloro-1,2-dithiolan-3-one, 5-chloro-4-phenyl-1,2-dithiolan-3-one, N-methylpyrrolidone , Phenyl- (2-cyano-2-chlorovinyl) sulfone, methylenebistiocyanate, 2-bromo-2-nitropropane-1,3-diol, 2,2- -Bromo-4'-hydroxyacetophenone, dibromonitrile propionamide, 2-bromo-2-bromomethylglutarnitrile, sodium percarbonate, potassium persulfate, sodium perborate, orthophenyl N-butyl p-hydroxybenzoate, methyl parahydroxybenzoate, benzalkonium chloride, benzethonium chloride, hydrochloric acid, hydrochloric acid, and the like. 2-pyridinethiol-1-oxide zinc salt, 2-pyridinethiol-1-oxide sodium, N, N'-hexamethylenebis (4-carbamoyl-1-decylpyridinium bromide), 4,4 '- (tetramethylenediamino) bis (1-decylpyridinium bromide), and the like.

Examples of the natural ophthalmic solution which can be used in the present invention include cineol, hinokitiol, menthol, terpineol, borneol, nopol, citral, citronellal, citronellol, Trimethylolpropane, linalool, dimethyloctanol, thymol and the like.

As the non-bleaching antimicrobial agent usable in the present invention, an iodine-based antimicrobial agent can be exemplified, and among these, a solid is particularly preferable. Examples of the iodine antimicrobial agent include 2,3,3-triiodoallyl alcohol, 2,3,3-triiodoallyl ethers, 2,3,3-triiodoallyl azoles, 3-iodo- (3-iodopropargyl) formate, iodopropargyl azoles, diiodomethyl paratolyl sulfone, povidone iodide, benzyl iodoacetic acid ester, and para-nitrobenzyl And iodoacetic acid esters.

These non-bleaching antimicrobial agents may be used alone or in combination of two or more.

(Inclusion compound type antibacterial agent)

These non-bleaching antimicrobial agents may be guest compounds of multi-molecular host compounds, for example, 2-bromo-2-nitropropane-1,3-diol, 5-chloro-2- Thiazolin-3-one or the like may be used as a guest compound to form an inclusion compound, which can be used as a non-bleaching antimicrobial agent.

In the present invention, the term "multi-molecular magnetic host compound" refers to a compound that forms a crystalline complex (inclusion compound) having a regular arrangement and interacting with an antimicrobial agent as a guest due to intermolecular forces such as hydrogen bonding, Is not particularly limited as long as it is a compound having an alkyl group, for example, the following compounds can be exemplified.

(1) tetrakisphenol

(2) 1,1,6,6-tetraphenyl-2,4-hexadiene-1,6-diol

(3) Synthesis of 1,6-bis (2-chlorophenyl) -1,6-diphenylhexane-2,4-diyne-1,6-diol

(4) 1,1,4,4-tetraphenyl-2-butyne-1,4-diol

(5) Synthesis of 2,5-bis (2,4-dimethylphenyl) hydroquinone

(6) Synthesis of 1,1-bis (2,4-dimethylphenyl) -2-propyn-

(7) Synthesis of 1,1,2,2-tetraphenylethane-1,2-diol

(8) 1,1'-Bis-2-naphthol

(9) 9,10-diphenyl-9,10-dihydroxyanthracene

(10) Synthesis of 1,1,6,6-tetra (2,4-dimethylphenyl) -2,4-hexadiyl-1,6-diol

(11) Synthesis of 9,10-bis (4-methylphenyl) -9,10-dihydroxyanthracene

(12) Synthesis of 1,1-bis (4-hydroxyphenyl) cyclohexane

(13) Synthesis of N, N, N ', N'-tetrakis (cyclohexyl) - (1,1'-biphenyl) -2-2'-dicarboxamide

(14) 4,4'-sulfonylbisphenol

(15) 4,4'-Butylidene bis (3-methyl-6-tert-butylphenol)

(16) Synthesis of 2,2'-methylenebis (4-methyl-6-tert-butylphenol)

(17) 4,4'-thiobis (4-chlorophenol)

(18) Synthesis of 2,2'-methylenebis (4-chlorophenol)

(19) Deoxycholic acid

(20) Cholsan

(21) α, α, α ', α'-tetraphenyl-1,1'-biphenyl-2,2'-dimethanol

(22) t-Butylhydroquinone

(23) Synthesis of 2,5-di-tert-butylhydroquinone

(24) Granular phase corn starch

(25) Synthesis of 1,4-diazabicyclo- (2,2,2) -octane

Examples of tetrakisphenols in the multi-molecular system host compound include 1,1,2,2-tetrakis (4-hydroxyphenyl) ethane, 1,1,2,2-tetrakis (3- Fluoro-4-hydroxyphenyl) ethane, 1,1,2,2-tetrakis (3-chloro-4-hydroxyphenyl) ethane, 1,1,2,2-tetrakis Tetrakis (3-methoxy-4-hydroxyphenyl) ethane, 1,1,2,2-tetrakis (3,5-dimethyl- (3-fluoro-4-hydroxyphenyl) propane, 1,1,3,3-tetrakis (4-hydroxyphenyl) propane, 1,1,3,3-tetrakis , 1,3,3-tetrakis (3-chloro-4-hydroxyphenyl) propane, 1,1,3,3-tetrakis Tetrakis (3-methoxy-4-hydroxyphenyl) propane, 1,1,3,3-tetrakis (3,5- Tetrakis (4-hydroxyphenyl) butane, 1,1,4,4-tetrakis (3- 4-hydroxyphenyl) butane, 1,1,4,4-tetrakis (3-chloro-4-hydroxyphenyl) butane, 1,1,4,4-tetrakis Tetrakis (3-methoxy-4-hydroxyphenyl) butane, 1,1,4,4-tetrakis (3,5-dimethyl- Hydroxyphenyl) butane, 1,1,5,5-tetrakis (4-hydroxyphenyl) pentane, 1,1,5,5-tetrakis (3-fluoro- Tetrakis (3-chloro-4-hydroxyphenyl) pentane, 1,1,5,5-tetrakis Tetrakis (3-methoxy-4-hydroxyphenyl) pentane, 1,1,5,5-tetrakis (3,5-dimethyl- ) Alkane may be specifically exemplified.

The inclusion compound which can be used in the present invention can be easily obtained by reacting a non-bleaching antimicrobial agent and a host compound, which are to be a guest, in the presence of water or an organic solvent, if necessary, by stirring at room temperature to 100 ° C for several minutes to several hours .

(Antimicrobial inorganic metal or compound thereof)

The antimicrobial inorganic metal or compound thereof may be added to the antifungal agent of the present invention. Is not particularly limited as long as it is a component containing an inorganic metal having antimicrobial properties, but is preferably a solid, and is preferably selected from particles of an antimicrobial inorganic metal itself or an oxide, a chloride, a nitrate, or a sulfate supported on a carrier.

Specific examples of the carrier include inorganic materials such as phosphates (zirconium phosphate, calcium phosphate and the like), metal oxides (silicon oxide, aluminum oxide, titanium oxide, zinc oxide, iron oxide and zirconium oxide) Silica gel, etc.) and the like. These carriers may be used singly or in combination of two or more kinds.

Among them, those having an antimicrobial inorganic metal oxide supported on a metal oxide carrier are more preferably selected from the viewpoint of supporting strength.

The antimicrobial inorganic metal or the antimicrobial inorganic metal in the compound is not particularly limited as long as it is a metal having antimicrobial activity, and silver, zinc, copper and the like are preferably selected. More preferably, silver is selected in terms of antibacterial effect. These antimicrobial inorganic metals may be used singly or in combination of two or more kinds.

The actual products of the antimicrobial inorganic metal or its compounds are not particularly limited as long as they are commercially available, and examples thereof include ATOMYBALL-S, ATOMYBALL-L, ATOMYBALL-UA (registered trademark, Nanoparticle silver-based inorganic antibacterial agent sold under the trade name of Kagaku Kogyo Co., Ltd. may be used.

The antimicrobial inorganic metal-containing component may be used alone or in combination of two or more.

As the blending amount of the antibacterial inorganic metal or its compound, for example, in the case of a component containing silver, it is preferably 0.0002 wt% or more in terms of the silver element concentration. More preferably, it is 0.0002 to 0.005% by weight. The antimicrobial activity is improved to 0.0002% by weight or more, and even if it is 0.005% by weight or less, the antimicrobial activity is sufficient and economically acceptable.

When the antimicrobial inorganic metal or its compound is in a particulate form, the average particle size of the dispersed particles in the composition is preferably 1 to 500 nm, more preferably 1 to 100 nm.

Here, the average particle diameter is a number average particle diameter, which is measured by a light scattering method. When the particle diameter is 500 nm or less, the dispersion state of the particles becomes stable. When the particle diameter is 100 nm or less, the dispersion state of particles becomes more stable. Further, the smaller the particle diameter, the more advantageous it is from the viewpoint of contact with the bacteria.

(Bacteria that can remove mucus)

Bacillus capable of removing mucus is specifically Bacillus subtilis (Bacillus subtilis), and Bacillus subtilis can be exemplified by natto bacteria.

(Other components)

The tablet of the present invention is usually added with other ingredients required for formulation, except when it can be prepared singly. Other components include excipients, binders, dissolution regulators, lubricants, surfactants, corrosion inhibitors, gels, antistatic agents, and other functional ingredients.

(Excipient, binder, dissolution regulator)

Examples of excipients, binders and solubilizers include organic acids such as fumaric acid, benzoic acid, adipic acid, succinic acid, sulfamic acid, dl-malic acid, citric acid, ascorbic acid, malonic acid, glycolic acid and C _10-24 saturated fatty acids; Inorganic acids such as boric acid; Lactose; Glucose; Cornstarch and others; Various kinds of cellulose such as crystalline cellulose, powdered cellulose, methylcellulose, ethylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, carboxymethylcellulose calcium, and hydroxypropylcellulose; Inorganic salts such as sodium chloride, magnesium sulfate, potassium sulfate, calcium hydrogen phosphate, synthetic aluminum silicate and magnesium triacetate; Polymeric compounds such as polyvinyl alcohol, polyvinylpyrrolidone, sodium alginate and gum arabic (powder); Sucrose fatty acid esters and the like, among which lactose; Glucose; Cornstarch and others; Cellulose such as crystalline cellulose, powdered cellulose and hydroxypropyl cellulose; It is preferable that the rubber (powder), polyvinyl alcohol, polyvinylpyrrolidone, dextrin and the like can improve the press formability, and toxic gas or the like does not react even when various detergents or the like are mixed therein. These excipients, binders and dissolution regulating agents may be added in a proportion of 1 to 99% by weight based on the total solid weight.

When calcium sulfate is used, calcium sulfate 0.5 hydrate is preferable from the viewpoint that formability and solubility can be easily controlled. Among the calcium sulfate 0.5 hydrate, the? Form produced by atmospheric pressure firing is produced by pressure firing is preferable because it is less likely to cause the mold collapse of the formed body due to absorption than that of the? type. When the? -type calcium sulfate 0.5 hydrate is used, the use of lactose in combination with lactose is more preferable in view of moldability and control of solubility .

_{Examples of} C _10-24 saturated fatty acids include stearic acid and lauric acid.

These saturated fatty acids are used for the purpose of imparting lubricity at the time of molding and improving the stability (swelling and collapse preventing property) of the agent in water. The saturated fatty acids are used in an amount of 1 to 10 % ≪ / RTI > by weight.

Hydroxypropyl cellulose refers to cellulose in which a part or all of the hydroxyl groups are substituted with 2- (CH ₂ CH (CH ₃ ) -O) _m H (where m is an integer of 1 or more) And is not particularly limited. Examples of the hydroxypropyl cellulose include hydroxypropylcellulose HPC-SL and HPC-L (trade name, manufactured by Nippon Soda Co., Ltd.). The amount of hydroxypropyl cellulose used in the present invention is preferably less than 5% by weight, more preferably 1 to 4% by weight, based on the total solids weight of the mucus control agent.

(Lubricant)

Examples of the lubricant include magnesium stearate, calcium stearate, sodium stearate, sodium benzoate, orthoboric acid, silica, talc, waxes and the like. These lubricants are used in an amount of 0.01 to 1% by weight It can be used as a ratio.

Talc is a hydrated silicate mineral of magnesium and has a composition of Mg ₃ Si ₄ O ₁₀ (OH) ₂ . In the present invention, it is used in place of or in combination with a surfactant. The content of talc is 0.1 to 10% by weight, preferably 0.5 to 3% by weight based on the total weight of the mucus control agent.

(Surfactants)

The surfactant used in the present invention is not particularly limited as long as it does not react with the antimicrobial component and has a melting point of 50 캜 or higher. When a surfactant having a melting point of 50 DEG C or lower is used, the tablets tend to dissolve in hot water or the like when used in kitchens or bathrooms, and in the summer, problems such as ease of bleaching of the surfactant from tablets . Examples of the surfactant having a melting point of 50 ° C or higher include fatty acid alkanolamides such as coconut fatty acid monoethanolamide and monoisopropanolamide laurate; Sorbitan fatty acid esters such as sorbitan stearate and sorbitan palmitate; Alkyl alkanolamides, sodium dialkylsulfosuccinate, sodium laurylsulfate, polyoxyethylene stearyl ether, polyoxyethylene polyoxypropylene block polymer and the like. Among them, palm oil fatty acid monoethanolamide and sorbitan stearate are preferable surfactants.

Of these, the following are commercially available. Examples of the palm oil fatty acid monoethanolamide include Tohor N-120 (manufactured by Toho Chemical Industry Co., Ltd.), Amisol CME (registered trademark, manufactured by Kawaken Fine Chemicals Co., Ltd.) and lauric acid monoisopropanolamide include Amizole PLME Sorbitan stearate such as Sorbitan SP-S10V, S20V, S30V (registered trademark, manufactured by Kao Corporation) and Sorbon S-60 (manufactured by Toho Chemical Industry Co., Ltd.) As the polyoxyethylene stearyl ether, Emulgen 350 (registered trademark, manufactured by Kao Corporation) and polyoxyethylene polyoxypropylene block polymer such as Newpol PE-40 (manufactured by Toho Chemical Industry Co., Ltd.) 68 (registered trademark, manufactured by Sanyo Chemical Industries, Ltd.).

These may be used alone or in admixture of two or more, but it is preferable to determine them in consideration of the influence on the stability, the solubility in water, the disintegration property, and the stability of the antimicrobial agent in the pressure molding.

The content of the surfactant is 0.1 to 10% by weight, preferably 0.5 to 3% by weight, based on the total weight of the mucoadhesive agent.

As a blend in the case of hot melt mixing or kneading extrusion molding, it is preferable that the blend is a solid at a temperature of 40 to 100 DEG C, and various water-soluble polymers such as polyoxyethylene, polyoxyethylene polyoxypropylene block polymer, polyoxyethylene Surfactants such as ethylene alkyl phenyl ether, polyethylene glycol fatty acid esters, glycerin fatty acid esters, polyoxyethylene alkyl ethers and the like.

(Corrosion inhibitor)

Examples of the corrosion inhibitor include alkylthiourea compounds and triazole compounds. When these compounds are used, corrosion of metal parts such as pipes and the like can be suppressed.

(Gel)

Examples of the gelling agent for use as the gel include agar, gelatin, locust bean gum, sodium alginate, polyvinyl alcohol, gum arabic, gellan gum, amino acid, carboxymethylcellulose and metal salts thereof, carrageenan and the like.

(Antistatic agent)

As the antistatic agent, an antistatic effect may be imparted upon molding by adding diatomaceous earth, sulfuric acid clay, or the like.

(Other functional components)

A compound having other functional components may be added. Other functional ingredients include a bitter taste-imparting ingredient for the purpose of preventing erosion of infants, a coloring ingredient for the purpose of improving the deodorizing component, the direction component, and the design property for the purpose of preventing malodor of the kitchen food garbage and the drainage port It can also be done by way of example.

(Elution concentration of the drug used for removing mucus)

In the present invention, the dissolution concentration of the drug used in the removal of the mucus is preferably as high as the concentration of the sterilizing component at the initial stage, and preferably at a certain concentration or more over a long period of time. In this case, the initial period is one day from the start of use, and the long term is at least 5 days, preferably at least 10 days, more preferably at least 15 days from the start of use. The elution concentration of the drug is determined in a timely manner because its effective concentration differs depending on the type of drug used for removing mucus, but it is preferably at least the minimum inhibition concentration.

The measurement of the dissolution concentration of the sterilizing component can be carried out, for example, as follows. The tablets for removing mucus of the present invention were filled in a cassette main body of a commercially available mucus remover for kitchen (Fig. 1, "Kitchen Hita (TM) disinfection mucus removing plastic type" Kao Company) ), And then set in a drainage port. Thereafter, water for one day was poured at a rate of 5 L / min for 5 minutes at a temperature of 37 to 42 DEG C for 18 hours to stop the running water for 55 minutes, Allow time. This process is repeated every day. Every 10 seconds after the washing water has been poured off every day, the cover and the cassette body are carefully taken out and placed in a 2 L poly cup at an angle to collect water adhering for 1 minute. The elution concentration of the sterilizing component of the collected water is measured. For example, when the drug used for mucus removal is 5-chloro-2-methyl-4-isothiazolin-3-one (CMI) Can be measured.

In the case of CMI, the concentration of the sterilizing component eluted at the initial stage can be about 1.2 times or more higher than that of the conventional tablets having no concave portion or through-hole on the surface when the sterilizing component and the blending amount thereof are the same, Or longer can be made longer than three days or 1.4 times longer than tablets having no recess or through hole in the prior art. In short, in conventional tablets, a period of time less than a predetermined concentration is long, whereas in the tablets of the present invention, by rapidly dissolving such a sterilizing component to a certain concentration or more, a period longer than a certain concentration can be made longer.

(Preparation and mixing ratio of tablets)

The method for producing the tablets of the present invention is not particularly limited, but is carried out by heat-melt mixing, kneading extrusion molding, pressure molding or the like with a medicine used for removing mucus and other components. The pressure-pressing method is preferable because concave portions and through holes can be formed at the same time depending on the machine type. The specific production method is as follows but need not be limited to this method.

First, each raw material is put into a Nauta mixer and mixed at room temperature (20 to 30 ° C) for 30 to 60 minutes. The mixed raw materials are passed through a rolling roller to perform plate-making (granulation). Once it is roughly crushed, it produces a raw powder. The raw noodles are fed from the hopper of the tablet machine and tableted. Tablets having recesses and through-holes are formed by the shape of the tablets. As a pressurizing tablet machine capable of forming a concave portion and a through hole, for example, a HER2 rotary tablet machine manufactured by Kikusui Seisakusho Co., Ltd. and the like can be given.

In the present invention, the mixing ratio of the drug used for removing the mucus and the other components is 1 to 99 parts by weight for the drug used for removing mucus in view of various uses, 99 to 1 part by weight But it is preferably 5 to 20 parts by weight for the agent used for mucus removal and 95 to 80 parts by weight for the other components. When an inclusion compound is used as a drug used for removing mucus, a blending ratio of 2 to 30 parts by weight of the inclusion compound and 98 to 70 parts by weight of the other components is preferable.

Example

Hereinafter, the present invention will be described in more detail with reference to examples and comparative examples, but the technical scope of the present invention is not limited to these examples at all.

(Preparation of sample)

A sample made of tablets having a diameter of 10 mm was prepared from each mixture having the mixing ratio shown in Table 1 by press molding. The mixing was carried out by a mixer of Magella type PT-60 manufactured by Kabushiki Kaisha, the assembly was carried out by a WP-160 pelletizer manufactured by Turbo Kogyo Co., Ltd., and by a HEL2 rotary tablet press manufactured by Kikusui Seisakusho Co., Ltd. In Table 1, "TOPBIT" (registered trademark) contains 2 mol of 5-chloro-2-methyl-4-isothiazolin-3-one (CMI) as an antimicrobial agent and 1 mol of 1 , 1,2,2-tetrakis (4-hydroxyphenyl) ethane, and "HPC" represents hydroxypropylcellulose.

(Dissolution test condition 1)

Twenty-four tablets (0.7 g / tablet) tableted with the composition shown in Table 1 were applied to a cassette main body of a commercially available mucus remover for kitchen shown in Fig. 1 ("KITCHEN HAITA (registered trademark) The water was set at a drain port and then water at a temperature of 37 to 42 ° C was flowed at a rate of 5 l / min for 5 minutes, and the water was stopped for 55 minutes. . This 1-hour treatment was carried out for 18 hours a day, and not for 6 hours. This one-day treatment was carried out for one day as shown in Table 2, and the lid and the cassette body were carefully taken out 10 seconds after the timely rinsing of the rinsing water in a timely manner. The lid and the cassette body were taken out at an angle, Respectively. The elution concentration of the sterilizing component of the collected water was measured. The measured concentration was determined as the measured value as the concentration converted into 5 g of water (concentration after correction = measured concentration x (weight of collected water (g) / 5 (g))). The measurement was carried out by liquid chromatography (column: Finepack SIL C18S 4.6? 占 150 mm, measurement wavelength: 275 nm, mobile phase: acetonitrile / water = 4/6, flow rate: 1.0 ml / min, internal table: dimethyl phthalate) And the concentration of the sterilizing component was recorded.

(Dissolution test condition 2)

The dissolution test was carried out in the same manner as in dissolution test 1 except that "treatment for 1 hour was carried out for 18 hours per day and treatment for 6 hours was not carried out" was replaced with "treatment for 1 hour was conducted 24 hours a day" The test was conducted under the condition 1.

(Examples 1 to 8 and Comparative Example 1)

Examples 1 to 7 and Comparative Examples were tested under the conditions of dissolution test condition 1, and Example 8 was tested under the conditions of dissolution test condition 2. Table 3 shows the strength of tablets tableted with the composition shown in Table 1, the concentrations of the eluted bactericide components are shown in Table 2, and the tablets after completion of the experiment are shown in Table 4. Table 5 shows the number of days when the weight of the tablets before the test becomes 50% or less.

(Concave portion)

In the case of a diameter of 10 mm, the thickness of the tablet is 6.2 mm, and the depth of the recess is 0.42 mm as shown in Fig.

When the diameter of the concave portion is 10 mm, the thickness is 6.2 mm, and the depth of the concave portion is 1.6 mm as shown in Fig.

In the case where the asymmetry is asymmetric, the depth of one recess is 2.6 mm and the depth of the recess on the opposite side is 1.0 mm when the diameter is 10 mm and the thickness is 6.0 mm, and the recess is the same as in Fig.

(Through hole)

In the case of a tablet having a diameter of 10 mm and a thickness of 6.2 mm, the diameter of the through hole is 2 mm (Fig. 5).

In the case of a diameter of 10 mm and a thickness of 6.2 mm, the diameter of the through hole is 3 mm.

(Feed shoe)

Agitation means stirring feed shoe, open means open feed shoe.

From Table 2, it was found that the initial concentration of the Example was higher than that of Comparative Example 1. It is to be noted that the comparative example shows that the concentration is not more than 2 ppm but not more than 13 days in Examples 1 to 5 and 8 or more in Examples 6 to 7, 12 days, whereas Examples 1 to 5 were later than the 17th day, Example 6 was later than the 15th day, and the long term sterilization component concentration was maintained. In Example 7, the number of days from 2 ppm or more to 1 ppm or less was a short period of time.

Since the dissolution test condition 2 is a test using 1.5 times the amount of water per day than the dissolution test condition 1, dissolution occurs earlier. However, since the water amount per day (water amount) is 1.5 times, the number of days is divided by 1.5, which is comparable to the dissolution test condition 1. From the result, it is found that Example 8 is easy to dissolve.

From Table 3, it was found that the tablet strength was not lowered.

From Table 4, it can be confirmed that the shape of the tablet at the end of the experiment is small, but the tablet is retained as a tablet. On the contrary, the embodiment is different from the initial shape, and the hole is punched or broken, It was found that the medicinal effect of the tablets was lost.

From Table 5, it was confirmed that the experiment was carried out at the dissolution rate equivalent to that of Comparative Example 1 even if the concave portion or the through hole was provided.

Industrial availability

In the conventional shape of the mucilage-removing tablets, the tablets became smaller with use and the surface area became smaller. As the surface area is decreased, the dissolution concentration of the sterilizing component is lowered, and mucus is generated even though the tablet is still present. For this reason, the user missed the exchange time of the tablets to generate mucus, or to exchange the tablets earlier than necessary.

In the tablet shape of the present invention, the tablet is reduced in size with use, but since the elution concentration of the sterilizing component is maintained at a predetermined concentration or more, no mucus is generated and the tablet shape is changed from the initial shape It is easy for the user to know when to exchange the tablets.

The effect of the present invention can be the same regardless of the sterilizing component and any component other than the sterilizing component, since it is an effect exhibited by the shape of the tablet. By appropriately adjusting the size of the concave portion and the size of the through hole, any tablet size can be used. Further, by adjusting the tableting conditions of the tablets, the concentration of the bactericidal component, and the kinds and ratios of components other than the bactericide, the initial concentration of the sterilizing component and the concentration of the constant concentration to be maintained for a long period of time can be appropriately changed.

Claims (2)

The time taken to be 50% or less of the total weight of the tablets in the continuous water flow, which is contained in a mucilage container having a structure in which the water is used in intermittent or continuous water flow, Characterized in that the tablet is a concave portion formed at the central portion of the upper surface of the tablet and / or the central portion of the tablet bottom surface, wherein the depth of the concave portion is 3 to 20 times the diameter of the tablet % Of the thickness of the tablets, or 5 to 30% of the thickness of the tablets. The method according to claim 1,
A mucilaginous tablet, which is a non-bleaching antimicrobial agent, for use in the removal of mucus from a mucus-removing tablet.

Images